Literature DB >> 14720082

Allocation of resources between smoking cessation methods and lovastatin treatment of hypercholesterolaemia: based on cost effectiveness and the social welfare function.

Pedro Plans-Rubió1.   

Abstract

OBJECTIVE: To use the social welfare function to decide on allocation of resources between smoking cessation methods and lovastatin treatment of hypercholesterolaemia for the primary prevention of coronary heart disease.
METHOD: Three smoking cessation therapies (medical advice, nicotine gum and nicotine patch) were considered in smokers, and lovastatin 20, 40 and 80 mg/day was considered in individuals with hypercholesterolaemia (total cholesterol > 7.24 mmol/L [> 270 mg/dL]). Multiple logistic regression analysis was used to obtain parameter epsilon determining the exact form of the social welfare function in Catalonia, Spain. The preferable strategy was to give higher priority to the intervention that used one smoking cessation method and lovastatin treatment for hypercholesterolaemia and that was associated with a value of epsilon consistent with the social welfare function.
RESULTS: A value of 1.58 (95% CI: 0.75-2.84) was obtained for parameter epsilon of the social welfare function, showing a nonutilitarian form. A higher priority should be given, based on the social welfare function, to the intervention using medical advice for smoking cessation and lovastatin 20-80 mg/day for hypercholesterolaemia, since this approach was associated with epsilon values of 2.8-2.9 in men and 1.8-2.4 in women, while interventions using nicotine substitution therapies were associated with epsilon values of < 0.9 in men and < 0.4 in women. The cost of treating all smokers and individuals with hypercholesterolaemia was 35% lower using medical advice for smoking cessation and lovastatin 20 mg/day, which was associated with epsilon values of 2.9 in men and 2.4 in women, than using a utilitarian solution consisting of nicotine patches for smoking cessation and lovastatin 20 mg/day.
CONCLUSION: These results show that higher priority should be given to lovastatin treatment of hypercholesterolaemia than to nicotine substitution treatments for smoking cessation, based on cost effectiveness and the social welfare function. The study also showed the applicability of this method to decisions about resource allocation between competing treatments when society has a nonutilitarian social welfare function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14720082     DOI: 10.2165/00019053-200422010-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  23 in total

1.  A note on the estimation of the equity-efficiency trade-off for QALYs.

Authors:  M Johannesson; U Gerdtham
Journal:  J Health Econ       Date:  1996-06       Impact factor: 3.883

Review 2.  Equity and equality in health and health care.

Authors:  A J Culyer; A Wagstaff
Journal:  J Health Econ       Date:  1993-12       Impact factor: 3.883

Review 3.  Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?

Authors:  S Birch; A Gafni
Journal:  J Health Econ       Date:  1992-10       Impact factor: 3.883

4.  Principles of cost-effective resource allocation in health care organizations.

Authors:  M C Weinstein
Journal:  Int J Technol Assess Health Care       Date:  1990       Impact factor: 2.188

5.  QALYs and the equity-efficiency trade-off.

Authors:  A Wagstaff
Journal:  J Health Econ       Date:  1991-05       Impact factor: 3.883

6.  Mathematical modeling strategies for the analysis of epidemiologic research.

Authors:  R S Greenberg; D G Kleinbaum
Journal:  Annu Rev Public Health       Date:  1985       Impact factor: 21.981

7.  How effective is nicotine replacement therapy in helping people to stop smoking?

Authors:  J L Tang; M Law; N Wald
Journal:  BMJ       Date:  1994-01-01

8.  Cost-effectiveness of cardiovascular prevention programs in Spain.

Authors:  P Plans-Rubió
Journal:  Int J Technol Assess Health Care       Date:  1998       Impact factor: 2.188

9.  The benefits of treating hyperlipidemia to prevent coronary heart disease. Estimating changes in life expectancy and morbidity.

Authors:  S A Grover; M Abrahamowicz; L Joseph; C Brewer; L Coupal; S Suissa
Journal:  JAMA       Date:  1992-02-12       Impact factor: 56.272

10.  Epidemiology of cardiovascular disease risk factors in Catalonia (Spain).

Authors:  P Plans; H Pardell; L Salleras
Journal:  Eur J Epidemiol       Date:  1993-07       Impact factor: 8.082

View more
  1 in total

Review 1.  Economic evaluations of cholesterol-lowering drugs: a critical and systematic review.

Authors:  Pearl D Gumbs; Monique W M Verschuren; Aukje K Mantel-Teeuwisse; Ardine G de Wit; Anthonius de Boer; Olaf H Klungel
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.